Roche's divarasib improved survival in previously treated KRAS G12C lung cancer

Roche's next-generation KRAS G12C inhibitor divarasib improved survival compared with sotorasib or adagrasib in a phase III trial of previously treated advanced or metastatic non-small cell lung cancer, reports said. The Krascendo 1 trial randomized 338 patients. Median overall survival was 17.7 months with divarasib and 12 months with the comparator drugs, and the trial reported a 44% lower risk of death. Median progression-free survival was 9.8 months versus 5.7 months.

Confirmed responses occurred in 58.4% of patients receiving divarasib and 32.3% of those receiving comparator drugs. Grade 3 or higher treatment-related side effects occurred in 24.6% versus 34.5%, according to MedPage Today. Gastrointestinal toxicities were more common with divarasib, at 91% versus 68.4%, but were mostly grade 1, the outlet reported. Medical Xpress reported that the results were published in the New England Journal of Medicine and presented at the ESMO Congress 2026.